Pregabalin in the treatment of chronic pain: An overview

S. Chiechio, M. Zammataro, F. Caraci, L. Rampello, A. Copani, A. F. Sabato, Ferdinando Nicoletti

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Chronic 'pathological' pain is sustained by mechanisms of peripheral and central sensitization, which are being increasingly investigated at the molecular and cellular levels. The molecular determinants of nociceptive sensitization are natural targets for potential analgesic drugs used in the treatment of different forms of pain. Most of these determinants are common to all forms of chronic pain, and it is therefore not surprising that drugs specifically targeted for the treatment of neuropathic pain are effective in relieving nociceptive inflammatory pain and vice versa. The molecular mechanisms of sensitization that occur in peripheral nociceptors and the dorsal horns of the spinal cord are putative targets for context-dependent drugs, i.e. drugs that are able to discriminate between 'normal' and 'pathological' pain transmission. Among these, pregabalin and gabapentin bind to the α2δ subunit of voltage-sensitive Ca2+ channels, which sustain the enhanced release of pain transmitters at the synapses between primary afferent fibres and second-order sensory neurons under conditions of chronic pain. Pregabalin in particular represents a remarkable example of a context-dependent analgesic drug that acts at a critical step of nociceptive sensitization. Preclinical and clinical data suggest that pregabalin is more than a structural and functional analogue of gabapentin and may be effective in the treatment of nociceptive inflammatory pain that is resistant to gabapentin.

Original languageEnglish
Pages (from-to)203-213
Number of pages11
JournalClinical Drug Investigation
Volume29
Issue number3
DOIs
Publication statusPublished - 2009

Fingerprint

Chronic Pain
Nociceptive Pain
Pain
Analgesics
Pharmaceutical Preparations
Central Nervous System Sensitization
Nociceptors
Neuralgia
Sensory Receptor Cells
Synapses
Therapeutics
gabapentin
Pregabalin
Spinal Cord Dorsal Horn

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Pregabalin in the treatment of chronic pain : An overview. / Chiechio, S.; Zammataro, M.; Caraci, F.; Rampello, L.; Copani, A.; Sabato, A. F.; Nicoletti, Ferdinando.

In: Clinical Drug Investigation, Vol. 29, No. 3, 2009, p. 203-213.

Research output: Contribution to journalArticle

Chiechio, S. ; Zammataro, M. ; Caraci, F. ; Rampello, L. ; Copani, A. ; Sabato, A. F. ; Nicoletti, Ferdinando. / Pregabalin in the treatment of chronic pain : An overview. In: Clinical Drug Investigation. 2009 ; Vol. 29, No. 3. pp. 203-213.
@article{e2b27f72df9a49bbacbc2ed8d0f77661,
title = "Pregabalin in the treatment of chronic pain: An overview",
abstract = "Chronic 'pathological' pain is sustained by mechanisms of peripheral and central sensitization, which are being increasingly investigated at the molecular and cellular levels. The molecular determinants of nociceptive sensitization are natural targets for potential analgesic drugs used in the treatment of different forms of pain. Most of these determinants are common to all forms of chronic pain, and it is therefore not surprising that drugs specifically targeted for the treatment of neuropathic pain are effective in relieving nociceptive inflammatory pain and vice versa. The molecular mechanisms of sensitization that occur in peripheral nociceptors and the dorsal horns of the spinal cord are putative targets for context-dependent drugs, i.e. drugs that are able to discriminate between 'normal' and 'pathological' pain transmission. Among these, pregabalin and gabapentin bind to the α2δ subunit of voltage-sensitive Ca2+ channels, which sustain the enhanced release of pain transmitters at the synapses between primary afferent fibres and second-order sensory neurons under conditions of chronic pain. Pregabalin in particular represents a remarkable example of a context-dependent analgesic drug that acts at a critical step of nociceptive sensitization. Preclinical and clinical data suggest that pregabalin is more than a structural and functional analogue of gabapentin and may be effective in the treatment of nociceptive inflammatory pain that is resistant to gabapentin.",
author = "S. Chiechio and M. Zammataro and F. Caraci and L. Rampello and A. Copani and Sabato, {A. F.} and Ferdinando Nicoletti",
year = "2009",
doi = "10.2165/00044011-200929030-00006",
language = "English",
volume = "29",
pages = "203--213",
journal = "Clinical Drug Investigation",
issn = "1173-2563",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - Pregabalin in the treatment of chronic pain

T2 - An overview

AU - Chiechio, S.

AU - Zammataro, M.

AU - Caraci, F.

AU - Rampello, L.

AU - Copani, A.

AU - Sabato, A. F.

AU - Nicoletti, Ferdinando

PY - 2009

Y1 - 2009

N2 - Chronic 'pathological' pain is sustained by mechanisms of peripheral and central sensitization, which are being increasingly investigated at the molecular and cellular levels. The molecular determinants of nociceptive sensitization are natural targets for potential analgesic drugs used in the treatment of different forms of pain. Most of these determinants are common to all forms of chronic pain, and it is therefore not surprising that drugs specifically targeted for the treatment of neuropathic pain are effective in relieving nociceptive inflammatory pain and vice versa. The molecular mechanisms of sensitization that occur in peripheral nociceptors and the dorsal horns of the spinal cord are putative targets for context-dependent drugs, i.e. drugs that are able to discriminate between 'normal' and 'pathological' pain transmission. Among these, pregabalin and gabapentin bind to the α2δ subunit of voltage-sensitive Ca2+ channels, which sustain the enhanced release of pain transmitters at the synapses between primary afferent fibres and second-order sensory neurons under conditions of chronic pain. Pregabalin in particular represents a remarkable example of a context-dependent analgesic drug that acts at a critical step of nociceptive sensitization. Preclinical and clinical data suggest that pregabalin is more than a structural and functional analogue of gabapentin and may be effective in the treatment of nociceptive inflammatory pain that is resistant to gabapentin.

AB - Chronic 'pathological' pain is sustained by mechanisms of peripheral and central sensitization, which are being increasingly investigated at the molecular and cellular levels. The molecular determinants of nociceptive sensitization are natural targets for potential analgesic drugs used in the treatment of different forms of pain. Most of these determinants are common to all forms of chronic pain, and it is therefore not surprising that drugs specifically targeted for the treatment of neuropathic pain are effective in relieving nociceptive inflammatory pain and vice versa. The molecular mechanisms of sensitization that occur in peripheral nociceptors and the dorsal horns of the spinal cord are putative targets for context-dependent drugs, i.e. drugs that are able to discriminate between 'normal' and 'pathological' pain transmission. Among these, pregabalin and gabapentin bind to the α2δ subunit of voltage-sensitive Ca2+ channels, which sustain the enhanced release of pain transmitters at the synapses between primary afferent fibres and second-order sensory neurons under conditions of chronic pain. Pregabalin in particular represents a remarkable example of a context-dependent analgesic drug that acts at a critical step of nociceptive sensitization. Preclinical and clinical data suggest that pregabalin is more than a structural and functional analogue of gabapentin and may be effective in the treatment of nociceptive inflammatory pain that is resistant to gabapentin.

UR - http://www.scopus.com/inward/record.url?scp=61349198712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61349198712&partnerID=8YFLogxK

U2 - 10.2165/00044011-200929030-00006

DO - 10.2165/00044011-200929030-00006

M3 - Article

C2 - 19243212

AN - SCOPUS:61349198712

VL - 29

SP - 203

EP - 213

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

SN - 1173-2563

IS - 3

ER -